Antolin, Albert A. http://orcid.org/0000-0002-1634-9034
Ameratunga, Malaka http://orcid.org/0000-0002-7171-6781
Banerji, Udai http://orcid.org/0000-0003-1503-3123
Clarke, Paul A. http://orcid.org/0000-0001-9342-1290
Workman, Paul http://orcid.org/0000-0003-1659-3034
Al-Lazikani, Bissan http://orcid.org/0000-0003-3367-2519
Article History
Received: 23 May 2019
Accepted: 21 January 2020
First Online: 17 February 2020
Competing interests
: A.A.A., M.A., U. B., P.A.C., P.W. and B.A.-L. are/were employees of The Institute of Cancer Research (ICR), which has a commercial interest in a range of drug targets, including protein kinases and are involved in a patent on the use of PARP inhibitors in BRCA-mutated cancers which results in commercial income. The ICR operates a Rewards to Inventors scheme whereby employees of the ICR may receive financial benefit following commercial licensing of a project. P.W. is a consultant/scientific advisory board member for Nextech Invest Ltd, Storm Therapeutics, Astex Pharmaceuticals, Nuevolution and CV6 and holds stock in Chroma Therapeutics, NextInvest and Storm Therapeutics; he is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Director of the non-profit Chemical Probes Portal. B.A.-L. is/was a consultant/scientific advisory board member for GSK, Open Targets, Astex Pharmaceuticals, Astellas Pharma and is an ex-employee of Inpharmatica Ltd. A.A.A., B.A.-L. and P.W. have been instrumental in the creation/development of canSAR and Probe Miner. B.A.-L was instrumental in the creation of ChEMBL.